Histogen’s Growth Factor Technology to be Marketed as part of Allergan Skin Care Line

Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that its proprietary multipotent cell conditioned media will be marketed by leading global biopharmaceutical company Allergan within its recently-acquired Regenica® Advanced Rejuvenation System.

The Multipotent Resignaling Complex (MRCxTM) within Regenica is made up of soluble cell-signaling proteins and growth factors which support the body’s epidermal stem cells that renew skin throughout life. Through Histogen’s technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal.

“Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements Allergan’s flagship growth factor technology – TNS,” said Rahul Mehta, Ph.D. Vice President, Research & Development at SkinMedica, an Allergan Company. “In addition to the Regenica product line, we are looking forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica’s commitment to evidence-based skincare.”

First created at Histogen as a three-product line for anti-aging and post-resurfacing, Regenica was licensed by Suneva Medical in 2012 and has grown to the current Advanced Rejuvenation System of six products sold through medical aesthetic professionals throughout the world. The acquisition of the product line by Allergan now expands the reach of the technology.

“Allergan’s world-class medical aesthetics portfolio, global footprint, history and commitment to developing innovative aesthetic products makes them ideally suited to realize the maximum potential of the Regenica growth factor technology for continued innovation in skincare,” said Dr. Gail Naughton, Histogen founder and inventor of its core technology.
Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension. Through this unique technology process, newborn cells are directed to naturally produce vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation.

For more information, please visit www.histogen.com